NcXHF

INDUSTRY AND ONCOLOGY
42. World Health Organization. Ethical Criteria for Medicinal Drug Promotion.1988.http://apps.who.int/iris/bitstream/10665/38125/1/924154239X_
eng.pdf?ua1. Accessed February 14, 2015.
43. Calfee JE. The role of marketing in pharmaceutical research and development.
Pharmacoeconomics. 2002;3:77-85.
44. Holmer AF. Direct-to-consumer advertising-strengthening our health
care system. N Engl J Med. 2002;346:526-528.
45. Kelly P. DTC advertising’s benefıts far outweigh its imperfections.
Health Aff (Millwood). 2004;W4-246-248.
46. Angell M. The Truth About Drug Companies: How They Deceive Us and
What to Do About It. New York: Random House, 2004.
47. Kravitz R. MSJAMA: direct to consumer advertising of prescription
drugs: implications for the physician-patient relationship. JAMA. 2000;
284:2244.
48. Wolfe SM. Direct-to-consumer advertising—education or emotion
promotion? N Engl J Med. 2002;346:524-526.
49. Weissman JS, Blumenthal D, Silk AJ, et al. Physicians report on patient
encounters involving direct-to-consumer advertising. Health Aff (Millwood).
2004:W4-219-233.
50. Weissman JS, Blumenthal D, Silk AJ, et al. Consumers’ reports on the
health effects of direct-to-consumer drug advertising. Health Aff (Millwood).
2003;W3-82-95.
51. Rosenthal MB, Berndt ER, Donohue JM, et al. Promotion of prescription
drugs to consumers. N Engl J Med. 2002;346:498-505.
52. Abel GA, Chen K, Taback N, et al. Impact of oncology-related directto-consumer
advertising: Association with appropriate and inappropriate
prescriptions. Cancer. 2013;119:1065-1072.
53. Drazen JM. The consumer and the learned intermediary in health care.
N Engl J Med. 2002;346:523-524.
54. Jagsi R. Conflicts of interest and the physician-patient relationship in
the era of direct-to-patient advertising. J Clin Oncol. 2007;25:902-905.
55. Avorn J. Powerful Medicines: The Benefıts, Costs, and Risks of Prescription
Drugs. New York: Alfred A. Knopf, 2004.
56. Kassirer JP. On the Take: How Medicine’s Complicity with Big Business
Can Endanger Your Health. Oxford: Oxford University Press,
2005.
57. Dana J, Loewenstein G. A social science perspective on gifts to physicians
from industry. JAMA. 2003;290:252-255.
58. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just
a gift? JAMA. 2000;283:373-380.
59. Ben-Shahar O, Schneider CE. The failure of mandated disclosure. Law
&EconomicsWorkingPapers.2010;Paper9.http://repository.law.umich.
edu/law_econ_current/art9.
60. Hall MA, Kidd KE, Dugan E. Disclosure of physician incentives: do
practices satisfy purposes? Health Aff (Millwood). 2000;19:156-164.
61. Miller TE, Horowitz CR. Disclosing doctors’ incentives: will consumers understand
and value the information? Health Aff (Millwood). 2000;19:149-155.
62. Miller TE, Sage WM. Disclosing physician fınancial incentives. JAMA.
1999;281:1424-1430.
63. Pharmaceutical Research and Manufacturers of America. 2013 Profıle:
Biopharmaceutical Research Industry. July 2013. http://www.phrma.
org/sites/default/fıles/pdf/PhRMA%20Profıle%202013.pdf. Accessed
on January 21, 2015.
asco.org/edbook | 2015 ASCO EDUCATIONAL BOOK 137